Gland Pharma Ltd

GLAND

Company Profile

  • Business description

    Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.

  • Contact

    TSIIC, Phase - IV
    Plot No. 11 and 84
    Pashamylaram (V), Patancheru M
    Sangareddy District
    HyderabadTG502307
    IND

    T: +91 8455699999

    https://www.glandpharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 March 2027

    Employees

    4,351

Stocks News & Analysis

stocks

Our top ASX picks in every sector

These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks

Tesla: Shares fall as deliveries come in below consensus

Long-term growth less reliant on auto sales.
stocks

Will Australia’s dwindling fuel supplies impact this share?

Australia’s petrol reserves have dropped from 60 to 35 days.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,921.2021.500.24%
CAC 408,060.9998.601.24%
DAX 4023,347.25179.170.77%
Dow JONES (US)46,669.88165.210.36%
FTSE 10010,468.4332.140.31%
HKSE25,116.53177.50-0.70%
NASDAQ21,996.34117.160.54%
Nikkei 22553,429.5615.880.03%
NZX 50 Index13,069.66243.791.90%
S&P 5006,611.8329.140.44%
S&P/ASX 2008,728.8043.800.50%
SSE Composite Index3,919.2929.27-0.74%

Market Movers